Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow the company to solicit from its stockholders the additional proxies necessary to obtain approval of the proposals described in the company's revised definitive proxy statement filed with the Securities and Exchange Commission on March 17, 2023.
The Special Meeting will reconvene on Thursday, May 4, 2023, beginning at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/AKBA2023SM. The record date for the Special Meeting continues to be the close of business on February 16, 2023. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. The proxy statement is available at https://www.sec.gov/ and at www.proxyvote.com.
Akebia encourages all stockholders of record at the close of business on February 16, 2023 who have not yet voted, to vote by 11:59 p.m. Eastern Time on May 3, 2023.
Akebia's board of directors strongly recommends that stockholders vote "FOR" each of the proposals presented at the Special Meeting.
https://finance.yahoo.com/news/akebia-therapeutics-announces-adjournment-special-151500531.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.